Innovative biotechnologies to restore soil health and improve agricultural competitiveness and resilience

Scope: Europe faces increasing challenges due to soil degradation, loss of biodiversity, and the expanding impacts of climate change. Addressing these issues is essential to ensure food security and sustainable land use. The integration of biotechnology can play a transformative role in this regard in the varied environmental conditions and land-use types found across Europe. In addition biotechnology solutions that improve soil health (such as novel bio-based fertilizers or microbial inoculants) can significantly enhance crop productivity by restoring essential nutrients and microbial balance in the soil. Finally, biotechnology solutions can provide innovative methods to decontaminate and rehabilitate degraded soils and lands, thus boosting the ecological and economic value of underutilized areas. Proposals should: develop, identify, upscale, pilot and validate biotechnology solutions, particularly leveraging the soil microbiome (such as novel bio-based fertilizers or microbial inoculants but not only) which remediate, restore and improve soil health across diverse pedoclimatic and cropping conditions; address the following issues: bioremediation of contaminated soils (i.e. by heavy metals, pharmaceuticals, PFAS); increasing soil organic carbon stocks, improving soil structure to enhance soil biodiversity, water retention and nutrient availability; overall, this should lead to enhanced crop quality and productivity, enabled higher and more sustainable biomass production; ensure that developed solutions are scalable, sustainable, cost-effective and integrate circular economy principles to boost resource efficiency and support sustainable soil management practices; assess the economic, environmental and social impact of developed biotechnological solutions; analyse their socio-economic feasibility (including cost-benefit, adoption barriers, and market potential) and validate their scalability and market readiness through stakeholder collaboration (e.g. SMEs, farmers, industry); address challenges related to environmental stability and sustainability of the developed solutions and the adaptability to varying environmental conditions; design integrated market-readiness pathways for the developed biotechnology solutions, to accelerate their safe, effective, and socially accepted deployment. The pathways should ensure regulatory compliance including risk assessment considerations, stakeholder engagement strategies, market acceptance analysis and policy foresight. Proposals must implement the 'multi-actor approach' and ensure adequate involvement of all relevant actors of the value chain, such as academia, research-technology organizations, small-medium enterprises (including start-ups), investors, product developers, intellectual property and legal advisors, manufacturing and distribution partners, as well as end-users, like farmers and practitioners. Proposals should include a dedicated task, appropriate resources and a plan on how they will collaborate with other project funded under this topic and other relevant topics. They should participate in joint activities, workshops, focus groups or social labs, as well as organise common communication and dissemination activities and show potential for upscaling and cross-fertilisation. Applicants should plan the necessary budget to cover these activities. null Activities are expected to achieve TRL 5-6 by the end of the project – see General Annex B.

Eligibility and submission conditions

"> General conditions 1. Admissibility Conditions: Proposal page limit and layout described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes. Proposal page limits and layout: described in Part B of the Application Form available in the Submission System. 2. Eligible Countries described in Annex B of the Work Programme General Annexes. A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide . 3. Other Eligible Conditions Proposals must apply the multi-actor approach. See definition of the multi-actor approach in the introduction to this work programme part. described in Annex B of the Work Programme General Annexes. 4. Financial and operational capacity and exclusion described in Annex C of the Work Programme General Annexes. 5a. Evaluation and award: Award criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes. 5b. Evaluation and award: Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual . 5c. Evaluation and award: Indicative timeline for evaluation and grant agreement described in Annex F of the Work Programme General Annexes. 6. Legal and financial set-up of the grants Eligible costs will take the form of a lump sum as defined in the Decision of 7 July 2021 authorising the use of lump sum contributions under the Horizon Europe Programme – the Framework Programme for Research and Innovation (2021-2027) – and in actions under the Research and Training Programme of the European Atomic Energy Community (2021-2025) [This [decision is available on the Funding and Tenders Portal, in the reference documents section for Horizon Europe, under ‘Simplified costs decisions’ or through this link: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/ls-decision_he_en.pdf ]]. described in Annex G of the Work Programme General Annexes. Specific conditions described in the [specific topic of the Work Programme] Application and evaluation forms and model grant agreement (MGA): Application form templates — the application form specific to this call is available in the Submission System Standard application form (HE RIA, IA) Evaluation form templates — will be used with the necessary adaptations Standard evaluation form (HE RIA, IA)   Guidance HE Programme Guide   Model Grant Agreements (MGA) Lump Sum MGA   Call-specific instructions   Detailed budget table (HE LS)   Guidance: "Lump sums - what do I need to know?" Additional documents: HE Main Work Programme 2026-2027 – 1. General Introduction HE Main Work Programme 2026-2027 – 12. Missions HE Main Work Programme 2026-2027 – 15. General Annexes HE Programme Guide HE Framework Programme 2021/695 HE Specific Programme Decision 2021/764 EU Financial Regulation 2024/2509 Decision authorising the use of lump sum contributions under the Horizon Europe Programme Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment EU Grants AGA — Annotated Model Grant Agreement Funding & Tenders Portal Online Manual   Funding & Tenders Portal Terms and Conditions   Funding & Tenders Portal Privacy Statement

Hivatkozott dokumentumok

Annex A Horizon Europe Programme Guide Online Manual [This [decision Standard application form (HE RIA, IA) Standard evaluation form (HE RIA, IA) Lump Sum MGA Detailed budget table (HE LS) Guidance: "Lump sums - what do I need to know?" HE Main Work Programme 2026-2027 – 1. General Introduction HE Main Work Programme 2026-2027 – 12. Missions Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment EU Grants AGA — Annotated Model Grant Agreement Funding & Tenders Portal Terms and Conditions